Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1206 participants.
Also called NCT03579914
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,206 participants
- Registry
-
NCT03579914
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03579914. Randomized; no masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2020-08-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
- Condition
- Anterior Myocardial Infarction
- Condition
- Heart Failure
- Intervention (Drug)
- intravenous Placebo
- Intervention (Drug)
- Metoprolol Injectable Product
- Intervention (Device)
- Romote Ischemic Conditioning (RIC)
- Intervention (Combination product)
- Metoprolol & RIC
- Lead sponsor
- Harbin Medical University
- Collaborator
- Beijing Chao Yang Hospital
Record details
- Record id
cardio:ct-nct03579914- Content hash
45e6830831d76bb887b91a60a3ac6656d69d39acd37aacc69ea5bc264bc6ec39